# E-DRUG: HGH Highly Gullible Humans **URL:** \ **Category:** e-drug\ **Created:** [January 17, 1999, 8:52pm UTC](https://talk.edrugplus.org/t/e-drug-hgh-highly-gullible-humans/4236 "1999-01-17T20:52:19Z")\ **Posts on this page:** 1\ **Page:** 1
**Author:** ![peter.mansfield](https://avatars.discourse-cdn.com/v4/letter/p/c77e96/32.png) [@peter.mansfield](https://talk.edrugplus.org/u/peter.mansfield)\ **Post date:** [January 17, 1999, 8:52pm UTC](https://talk.edrugplus.org/t/e-drug-hgh-highly-gullible-humans/4236/1 "1999-01-17T20:52:19Z")
E-drug: HGH Highly Gullible Humans --------------------------------------------- This ad is likely to be effective because it tells people what they want to hear - that we can get things we desire quickly and easily. It appears that the ad has been written on the basis of research about people rather than about the drug. That is not new. Perhaps the best response to this is to try to teach everyone that if someone tells you want you want to hear and asks for money then you can not trust them. Re circulation of ads on E-drug. I suggest that in E-druggers (like me) who are concerned about promotion on the Internet circulate the URL etc rather than the promotion itself so that only those of us who are interested have to read it. regards, Peter Dr Peter Mansfield Director, MaLAM MaLAM encourages pharmaceutical companies to provide more reliable information to assist appropriate health care. MaLAM Headquarters PO Box 172, Daw Pk SA 5041, Australia phone/fax +61 8 8374 2245 peter.mansfield@flinders.edu.au [http://www.camtech.net.au/malam](http://www.camtech.net.au/malam) [Note: Peter informs us that the Therapeutic Goods Administration (Australia) has already been approached to deal with this sort of promotion on the Internet. It will be interesting to see what sort of control mechanism can be developed. BS. Co-Moderator] -- Send mail for the `E-Drug' conference to `e-drug@usa.healthnet.org'. Mail administrative requests to `majordomo@usa.healthnet.org'. For additional assistance, send mail to: `owner-e-drug@usa.healthnet.org'.